The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk’s drug, Ozempic, for the treatment of chronic kidney disease in adults with type 2 diabetes. This approval expands the drug’s current usage, which was previously limited to managing blood sugar levels in diabetic patients. The decision is based on clinical trial data demonstrating Ozempic’s effectiveness in slowing the progression of kidney disease and reducing the risk of major adverse cardiovascular events in this patient population. This approval marks a significant development in the treatment of kidney disease among individuals with type 2 diabetes.